Home

Christoph H Westphal

CIK 1291961 · President and CEO · last filed 2021-07-22

Christoph H Westphal is a President and CEO who has filed 106 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for TCRX, was dated Jul 22, 2021. Across all open-market trades the lifetime net is +$13.6M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $831.8K across reported positions. 3 SEC filings were submitted jointly with ALNYLAM PHARMACEUTICALS, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$831.8K

Companies

5

Total Filings

106

Lifetime Open-Market Net

$13.59M

Filer Profile

Reported Address
C/O ALNYLAM PHARMACEUTICALS, INC
300 THIRD STREET
CAMBRIDGE, MA 02142
Related Filers
ALNYLAM PHARMACEUTICALS, INC. — 3 joint filings, latest 2004-06-07
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TCRX 10%+ Owner 1,036,585 $0.32 $329.5K $2.00M 1 2021-07-22
Salarius Pharmaceuticals, Inc. (FLKS) Delisted President and CEO 157,645 — — $3.19M 65 2018-10-18
VSTM Executive Chairman 65,911 $7.62 $502.2K $8.08M 28 2015-07-01
Tempest Therapeutics, Inc. (OVAS) Delisted Director 47,118 — — $1.05M 3 2014-03-11
Sirtris Pharmaceuticals, Inc. (SIRT) Delisted President and CEO 744,053 — — -$733.3K 8 2008-05-30

Recent Filings

106 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-07-22 TCRX Mixed +1,278,838 $2.00M EDGAR
2018-10-18 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Sell (S) −3,212,861 -$2.94M EDGAR
2017-07-27 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Grant (A) — $0 EDGAR
2016-11-08 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Buy (P) +7,000 $51.2K EDGAR
2016-11-07 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Buy (P) +8,870 $50.6K EDGAR
2016-06-24 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Buy (P) +2,700 $30.5K EDGAR
2016-06-22 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Buy (P) +5,700 $63.0K EDGAR
2016-06-21 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Buy (P) +6,000 $67.0K EDGAR
2016-06-17 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Buy (P) +5,800 $64.8K EDGAR
2016-06-15 Salarius Pharmaceuticals, Inc. (FLKS) Delisted Buy (P) +5,900 $68.1K EDGAR
Showing 1–10 of 106
Page 1 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.